Virpax Pharmaceuticals
Virpax - Model Epoladerm -Diclofenac Topical Spray Film
Improved drying, less messy, and better bioavailability; Reliable and reproducible blood levels; Improved patient compliance that could result in enhanced therapeutic outcomes; Sustained pain control over 24 hours with one application.
Most popular related searches
drug application
anti-inflammatory
inflammatory analgesic
inflammatory anti
inflammatory action
drug target
patient blood
drug synthesis
inflammatory mechanisms
TARGET MARKET
Osteoarthritis of the knee
DELIVERY SYSTEM
Topical spray film
MECHANISM OF ACTION
Topical Diclofenac Epolamine has an anti-inflammatory/antipyretic/analgesic action due to the inhibition of prostaglandin synthesis by inhibition of cyclooxygenase.
NEW DRUG APPLICATION (NDA)
As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue an accelerated 505(b)(2) New Drug Application for Epoladerm.